Literature DB >> 2424984

Alloantigen-specific suppressor T cells are not inhibited by cyclosporin A, but do require IL 2 for activation.

R P Bucy.   

Abstract

Alloantigen-specific suppressor T cells are activated from normal murine spleen cells in mixed lymphocyte reactions (MLR). These T cells are radioresistant and suppress the activation of cytotoxic T lymphocytes (CTL) in second primary MLR cultures. This report demonstrates that cyclosporin A (CsA) blocks the activation of these suppressor cells at a dose of 1 microgram/ml. However, reconstitution of CsA blocked cultures with IL 2 restores the activation of the suppressor T cells, but fails to significantly restore the activation of CTL in these same cultures. This differential activation requirement was used to establish T cell lines that demonstrate enriched suppressor cell activity but depletion of CTL activity. These findings are discussed in terms of the mechanism of action of CsA in these distinct T cell subsets and the relevance to models of allograft unresponsiveness.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424984

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  Identification and characterization of CD8+ suppressor T cells.

Authors:  James C Zimring; Judith A Kapp
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Differential sensitivity of CD8+ suppressor and cytotoxic T lymphocyte activity to bacterial monophosphoryl lipid A.

Authors:  F Esquivel; C E Taylor; P J Baker
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

Review 3.  Special regulatory T-cell review: Suppressors regulated but unsuppressed.

Authors:  Judith A Kapp
Journal:  Immunology       Date:  2008-01       Impact factor: 7.397

Review 4.  The influence of cyclosporin A on cell-mediated immunity.

Authors:  A W Thomson; L M Webster
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 6.  Regulation of lymphocyte growth by antagonists of interleukin-2 or its cellular receptor.

Authors:  G N Gaulton; J F Markmann
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.